Novosibirsk pharmaceutical company Renewal (PFK “Obnovleniie”) plans to start producing the drug “L-thyroxine Renewal” in mid-April. The production of the drug, which is intended for the treatment of thyroid hormone deficiency, will amount to up to 200,000 packages per month. This was announced by Vladimir Grechkin, the company’s executive director.
“The company plans to provide the pharmaceutical market of Russia with an uninterrupted supply of the drug in the required quantity. We are planning to launch production within two weeks, as soon as we receive the registration documents. Technically, we are prepared, and have the necessary raw materials and components for the production. We produce the drug at our available capacities,” TASS quotes Grechkin as saying.
According to him, the drug is necessary for replacement therapy in hypothyroidism, a condition caused by a prolonged lack of thyroid hormones. Vladimir Grechkin also noted that thyroid diseases account for the second place in the structure of endocrine pathology.
“Drugs manufactured abroad account for more than 90% of the market. The register of medicines features two manufacturers of this drug that are from the Russian Federation, including Renewal. Technically, the existing manufacturers are able to cover 100% of the need for these drugs for all patients of the Russian Federation. We are currently working to compensate for the deficiency of the drug in pharmacies in the country, and we will produce as many packages of the product as customers need,” the source said.
Mikhail Murashko, the Minister of Health of the Russian Federation, previously reported on the facts of the absence of certain medicines in the country, in particular, Levothyroxine, which is used for thyroid disease. In the first week of March, its sales increased tenfold, and in the second, five times. Patients taking these drugs stocked on them in large quantities.
